Search

Your search keyword '"Kearns, PR"' showing total 3 results
Start Over Author "Kearns, PR" Database OAIster
3 results on '"Kearns, PR"'

1. The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global

Author

Moreira, DC, Sniderman, E, Mukkada, S, Chantada, G, Bhakta, N, Foster, W, Avula, M, Homsi, MR, Faughan, L, Happ, B, Andujar, A, Sonnenfelt, J, Dalvi, R, Frazier, AL, Hessissen, L, Kearns, PR, Luna-Fineman, S, Moreno, A, Saghir Khan, M, Sullivan, M, Devidas, M, Santana, V, Caniza, M, Pritchard-Jones, K, Rodriguez-Galindo, C, Moreira, DC, Sniderman, E, Mukkada, S, Chantada, G, Bhakta, N, Foster, W, Avula, M, Homsi, MR, Faughan, L, Happ, B, Andujar, A, Sonnenfelt, J, Dalvi, R, Frazier, AL, Hessissen, L, Kearns, PR, Luna-Fineman, S, Moreno, A, Saghir Khan, M, Sullivan, M, Devidas, M, Santana, V, Caniza, M, Pritchard-Jones, K, and Rodriguez-Galindo, C

Abstract

The COVID-19 pandemic quickly led to an abundance of publications and recommendations, despite a paucity of information on how COVID-19 affects children with cancer. This created a dire need for a trusted resource with curated information and a space for the pediatric oncology community to share experiences. The Global COVID-19 Observatory and Resource Center for Childhood Cancer was developed, launched, and maintained by the International Society of Pediatric Oncology and St. Jude Children's Research Hospital. The three components (Resource Library, Global Registry, and Collaboration Space) complement each other, establishing a mechanism to generate and transfer knowledge rapidly throughout the community.

Published
2021

2. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference

Author

Horton, T, Sposto, R, Brown, P, Reynolds, C, Hunger, S, Winick, N, Raetz, E, Carroll, W, Arceci, R, Borowitz, M, Gaynon, P, Gore, L, Jeha, S, Maurer, B, Siegel, S, Biondi, A, Kearns, P, Narendran, A, Silverman, L, Smith, M, Zwaan, C, Whitlock, J, Horton, TM, Reynolds, CP, Hunger, SP, Winick, NJ, Raetz, EA, Carroll, WL, Arceci, RJ, Borowitz, MJ, Gaynon, PS, Maurer, BJ, Siegel, SE, BIONDI, ANDREA, Kearns, PR, Silverman, LB, Smith, MA, Zwaan, CM, Whitlock, JA, Horton, T, Sposto, R, Brown, P, Reynolds, C, Hunger, S, Winick, N, Raetz, E, Carroll, W, Arceci, R, Borowitz, M, Gaynon, P, Gore, L, Jeha, S, Maurer, B, Siegel, S, Biondi, A, Kearns, P, Narendran, A, Silverman, L, Smith, M, Zwaan, C, Whitlock, J, Horton, TM, Reynolds, CP, Hunger, SP, Winick, NJ, Raetz, EA, Carroll, WL, Arceci, RJ, Borowitz, MJ, Gaynon, PS, Maurer, BJ, Siegel, SE, BIONDI, ANDREA, Kearns, PR, Silverman, LB, Smith, MA, Zwaan, CM, and Whitlock, JA

Abstract

One of the challenges of incorporating molecularly targeted drugs into multi-agent chemotherapy (backbone) regimens is defining dose-limiting toxicities (DLTs) of the targeted agent against the background of toxicities of the backbone regimen. An international panel of 22 pediatric acute lymphocytic leukemia (ALL) experts addressed this issue (www.ALLNA.org). Two major questions surrounding DLT assessment were explored: (1) how toxicities can be best defined, assessed, and attributed; and (2) how effective dosing of new agents incorporated into multi-agent ALL clinical trials can be safely established in the face of disease- and therapy-related systemic toxicities. The consensus DLT definition incorporates tolerance of resolving Grade 3 and some resolving Grade 4 toxicities with stringent safety monitoring. This functional DLT definition is being tested in two Children's Oncology Group (COG) ALL clinical trials. © 2010 Wiley-Liss, Inc.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results